CNBC
US · 1 hrs ago
Botox maker Galderma sees early boost from 'Ozempic face' trend as GLP-1 use climbs, CEO says
The aestetics company hope increased GLP-1 use will fuel demand for treatments addressing facial volume loss, sometimes dubbed "Ozempic face."
Do you trust CNBC?
Sign in to rate
Discussion
?
No comments yet — be the first to start the discussion!